HealthRX vs Peter MD
Two GLP-1 desks, one scoreboard. We put HealthRX and Peter MD head-to-head on the published Brief Score — the same six factors, scored the same way.
HealthRX
The verdict
HealthRX takes this head-to-head.
HealthRX scores 86 to 76 on our six-factor Brief Score — A LegitScript-certified, physician-supervised desk (healthrx.com) whose real hook is breadth: injectable and a rare oral GLP tablet, on both molecules, with transparent no-insurance monthly pricing.
That doesn't make Peter MD a bad call — it's best for readers who want glp-1 care bundled with trt, sermorelin, nad+ or hair-loss treatment on a single account, and are comfortable reading a tiered price ladder rather than one flat monthly figure this site can map straight onto a dose. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| HealthRX | Peter MD | |
|---|---|---|
| Brief Score | 86/100 (B) | 76/100 (C) |
| Semaglutide | $189/mo | $149/mo new-user tier · $139/mo returning-user tier (GLP1 + B12) |
| Tirzepatide | $349/mo | $249/mo after a $149 first month (billed quarterly, 60mg) |
| Coverage | Not publicly listed | Most states — exclusions vary by treatment (not a single list) |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
HealthRX: Company-stated tiers held flat this cycle; the LegitScript badge and a rare oral GLP tablet are the draw, but some tiers are self-reported rather than checkout-verified.
Peter MD: First reading, 2026-08-04: tirzepatide runs $149 the first month before resetting to $249 on quarterly billing; compounded semaglutide (sold as GLP1 + B12) splits into a $149/mo new-user tier and a $139/mo returning-user tier rather than one flat monthly rate.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.